A novel and unusual utility of the cardiosintol drug as a fluoro-prober in the amendment of a highly fluorescent module for determining the non-fluorescent N-acetylcysteine drug.

It is common to use reagents to determine the drugs by exploiting the properties of these reagents in the development of fluorescence of the target drug or sometimes increasing its intensity; this is the usual and predominant in the methods used in various techniques. But using a drug as a reagent to analyze another drug is unique, unusual, and uncommon; that's the idea of this paper. This is possible by creating a chemical modulation in the drug's structure using another drug. Targeted analyte molecules (N-acetylcysteine, as an example) that lack fluorogenic or chromophoric moieties cannot be monitored or evaluated without undergoing structural modification. Thus, the chemical mending of the analyte's molecular structure can achieve the transformational process. This protocoled analytical method generates an amended fluorescence sensation that can be chased fluorimetrically at 441 nm (emission) following excitation at 339 nm. When o-dialdehyde, diformylbenzene, a non-fluorescent moiety, is added to a solution of non-fluorescent analyte in the presence of cardiosintol drug, at a specific pH, the target drug-thiol moiety can be amended into a highly fluorescent compound. This study presented a sensitive and feasible fluorometric test for acetylcysteine. The response is linear throughout the range of 0.05-0.80 µg mL. Quantum yield and procedure validation were evaluated according to I.C.H. standards. The formed mutated product was successfully applied to the precise assessment of the studied drug in batch powder and dose form(s), with no impact from excipients. Compared to the referenced publication, the outcomes demonstrate remarkable precision and accuracy.